Nova Mentis Assigns Intellectual Property Aug 27, 2024 09:00AM
Nova Mentis Announces Change of Directors Feb 26, 2024 08:30AM
Nova Mentis Applauds Government Decision to Create Rare Disease Advisory Group Nov 3, 2023 08:30AM
Nova Mentis Announces Participant Screening Underway in Canada's First Psilocybin Clinical Trial for Fragile X Syndrome Aug 30, 2023 08:30AM
Nova Mentis to Enter mRNA AI Diagnostics Business Apr 26, 2023 08:30AM


Apr 18, 2023 08:30AM Wellbeing Subsidiary KGK Science Begins Recruitment in First-of-its-Kind Health Canada Approved Psilocybin Trial
Apr 18, 2023 08:30AM Nova Mentis Begins Recruitment in First-of-its-Kind Health Canada Psilocybin Trial
Apr 11, 2023 08:30AM Wellbeing Subsidiary KGK Science Receives Institutional Review Board Approval
Apr 11, 2023 08:30AM Nova Mentis Receives Institutional Review Board Approval to Commence Psilocybin Clinical Trial
Apr 5, 2023 08:30AM Nova Mentis Provides Corporate Update and 2023 Outlook
Mar 29, 2023 08:30AM Novel Therapeutic Solutions are Needed as Autism Rates Increase
Feb 14, 2023 08:30AM Wellbeing Subsidiary KGK Science Receives Exemption Under Section 56 of the Controlled Drugs and Substances Act to Begin Psilocybin Clinical Trial
Feb 14, 2023 08:30AM Nova Mentis Granted Health Canada Section 56 Exemption to Begin Psilocybin Clinical Trial
Jan 18, 2023 08:30AM Nova Mentis Appoints Derek Ivany as Executive Chairman
Dec 22, 2022 04:15PM Wellbeing Subsidiary KGK Science Receives Approval for First-of-its-Kind Psylocibin Clinical Trial
Dec 22, 2022 12:21PM Nova Mentis Receives Health Canada Approval for First-Of-Its-Kind Psilocybin Clinical Trial
Dec 8, 2022 08:30AM Nova Mentis' Psilocybin Preclinical Study Published in International Science Journal
Nov 30, 2022 08:30AM Wellbeing Subsidiary KGK Science Submits CTA for Phase IIA Clinical Trial
Nov 30, 2022 08:30AM Nova Submits Phase II A Psilocybin Clinical Trial Application to Health Canada
Nov 17, 2022 08:30AM Wellbeing Subsidiary KGK Science Enters into Research Contract With Nova Mentis for Phase II A Clinical Trial
Nov 17, 2022 08:30AM Nova Mentis Enters into Research Contract with KGK Science for Phase II A Clinical Trial
Sep 29, 2022 08:30AM Nova Mentis Psilocybin Microdose Capsule Formulation to be Submitted in Health Canada Phase 2A Clinical Trial Application
Sep 15, 2022 08:30AM Nova Mentis Completes Production of Psilocybin Microdose Capsules
Jul 11, 2022 08:30AM Nova Mentis to Present Promising Psilocybin Microdose Data at 18th NFXF International Fragile X Conference
Jun 22, 2022 08:30AM Nova Mentis to Present at the H.C. Wainwright Mental Health Conference
Jun 16, 2022 08:30AM Nova Mentis Files Patent on Diagnosing, Monitoring and Treating Neurological Diseases with Psychoactive Tryptamine Derivatives
Jun 9, 2022 08:30AM Nova Mentis and University of Central Florida to Develop Saliva Serotonin Assay
Jun 7, 2022 08:30AM Nova Mentis Receives Controlled Substances Export Approval From The U.S. DEA For The Company's Proprietary Psilocybin Drug NM 1001
May 12, 2022 08:30AM Nova Mentis Welcomes Autism Behaviour Analyst to its Science Team
Mar 23, 2022 08:30AM Nova Mentis Begins Enrollment in North American Autism Study
Mar 15, 2022 08:30AM Nova Mentis Announces Closing of Non-Brokered Financing
Feb 16, 2022 08:00AM Nova Mentis Study Confirms Oral Microdose Psilocybin Treatment of Autism
Dec 16, 2021 08:30AM Nova Mentis and Mycrodose Therapeutics Announce Major Milestone with Transdermal Technology for Fragile X Syndrome Clinical Program
Nov 9, 2021 08:30AM Nova Mentis Files Genetic Neuroinflammatory Disease Patent
Nov 2, 2021 08:30AM U.S. FDA Approves Nova Mentis Orphan Drug Application
Oct 26, 2021 08:00AM Nova Mentis Earns Psilocybin Orphan Drug Designation in Europe for Fragile X Syndrome
Oct 19, 2021 08:00AM Mycrodose Therapeutics and Nova Mentis Announce LOI to Co-Develop Advanced Drug Delivery System